drugset

drugset / Trial / NCT02536469

HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors

NCT02536469 ↗

Phase 1 Completed 15 enrolled Bristol-Myers Squibb This trial was conducted previously by Cormorant · collab

NaSingle-groupOpen-labelTreatment

Summary

A phase Ib, dose escalation, multiple dose trial with HuMax-IL8 in patients with metastatic or unresectable, locally advanced malignant solid tumors.

Timeline

Start: 2015-08
Primary completion: 2016-11
Completion: 2016-11

Publications

Bilusic M, Heery CR, Collins JM, Donahue RN, Palena C, Madan RA, Karzai F, Marte JL, Strauss J, Gatti-Mays ME, Schlom J, Gulley JL. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. J Immunother Cancer. 2019 Sep 5;7(1):240. doi: 10.1186/s40425-019-0706-x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ADAKITUG	Monoclonal antibody	32 mg/kg	Intravenous

Indications